The DOI matches its Crossref record; 42 of the 42 references it cites were found in a registry or an index.
Chronic lymphocytic leukemia B cells contain anomalous Lyn tyrosine kinase, a putative contribution to defective apoptosis
Open accessAbstract
B cell chronic lymphocytic leukemia (B-CLL) is a neoplastic disorder characterized by accumulation of B lymphocytes due to uncontrolled growth and resistance to apoptosis. Analysis of B cells freshly isolated from 40 patients with chronic lymphocytic leukemia demonstrated that the Src kinase Lyn, the switch molecule that couples the B cell receptor to downstream signaling, displays anomalous properties. Lyn is remarkably overexpressed at the protein level in leukemic cells as compared with normal B lymphocytes, with a substantial aliquot of the kinase anomalously present in the cytosol. Whereas in normal B lymphocytes Lyn activation is dependent on B cell-receptor stimulation, in resting malignant cells, the constitutive activity of the kinase accounts for high basal protein tyrosine phosphorylation and low responsiveness to IgM ligation. Addition of the Lyn inhibitors PP2 and SU6656 to leukemic cell cultures restores cell apoptosis, and treatment of malignant cells with drugs that induce cell apoptosis decreases both activity and amount of the tyrosine kinase. These findings suggest a direct correlation between high basal Lyn activity and defects in the induction of apoptosis in leukemic cells. They also support a critical role for Lyn in B-CLL pathogenesis and identify this tyrosine kinase as a potential therapeutic target.
Overview
The claims and statistics of this paper haven’t been checked yet.
Free: it reads the open-access text and checks the first 5 claims that cite a source we can check. Create a free account to check every claim.
Integrity signals
Registry
Cites
Statistics
Verification
Claims the paper makes
The claims and statistics of this paper haven’t been checked yet.
Free: it reads the open-access text and checks the first 5 claims that cite a source we can check. Create a free account to check every claim.
Self-check
Percentages, sums and reported differences re-computed from the paper’s own numbers.
The self-check needs the paper’s full text.
Citations
Cites
Harris, N., Jaffe, E., Stein, H., Banks, P., Chan, J., Cleary, M., Delsol, G., De Wolf- Peeters, C., Falini, B., & Gatter, K. (1994) · Blood · doi:10.1182/blood.v84.5.1361.1361 · Cited by 6,327
FUNCTIONS OF LIPID RAFTS IN BIOLOGICAL MEMBRANES
Brown, D. A., & London, E. (1998) · Annual Review of Cell and Developmental Biology · doi:10.1146/annurev.cellbio.14.1.111 · Cited by 2,948
Clinical staging of chronic lymphocytic leukemia
Rai, K., Sawitsky, A., Cronkite, E., Chanana, A., Levy, R., & Pasternack, B. (1975) · Blood · doi:10.1182/blood.v46.2.219.219 · Cited by 2,784
Cheson, B., Bennett, J., Grever, M., Kay, N., Keating, M., O'Brien, S., & Rai, K. (1996) · Blood · doi:10.1182/blood.v87.12.4990.bloodjournal87124990 · Cited by 1,819
Three-dimensional structure of the tyrosine kinase c-Src
Xu, W., Harrison, S. C., & Eck, M. J. (1997) · Nature · doi:10.1038/385595a0 · Cited by 1,418
The specificities of protein kinase inhibitors: an update
BAIN, J., McLAUCHLAN, H., ELLIOTT, M., & COHEN, P. (2003) · Biochemical Journal · doi:10.1042/bj20021535 · Cited by 1,369 · cited 3×
“Accordingly, the combined use of these two inhibitors has been suggested for identifying the specific physiological roles of Src kinases (21).”
Inhibition of acute lymphoblastic leukaemia by a Jak-2 inhibitor
Meydan, N., Grunberger, T., Dadi, H., Shahar, M., Arpaia, E., Lapidot, Z., Leeder, J. S., Freedman, M., Cohen, A., Gazit, A., et al. (1996) · Nature · doi:10.1038/379645a0 · Cited by 897
Regulation of B-cell fate by antigen-receptor signals
Niiro, H., & Clark, E. A. (2002) · Nature Reviews Immunology · doi:10.1038/nri955 · Cited by 629
Activation of the Sire-family tyrosine kinase Hck by SH3 domain displacement
Moarefi, I., LaFevre-Bernt, M., Sicheri, F., Huse, M., Lee, C.-H., Kuriyan, J., & Miller, W. T. (1997) · Nature · doi:10.1038/385650a0 · Cited by 601
Cambier, J. C. (1995) · The Journal of Immunology · doi:10.4049/jimmunol.155.7.3281 · Cited by 459
INITIATION AND PROCESSING OF SIGNALS FROM THE B CELL ANTIGEN RECEPTOR
Reth, M., & Wienands, J. (1997) · Annual Review of Immunology · doi:10.1146/annurev.immunol.15.1.453 · Cited by 437
Chronic lymphocytic leukemia: revelations from the B-cell receptor
Stevenson, F. K., & Caligaris-Cappio, F. (2004) · Blood · doi:10.1182/blood-2003-12-4312 · Cited by 390
Lipid rafts and B-cell activation
Pierce, S. K. (2002) · Nature Reviews Immunology · doi:10.1038/nri726 · Cited by 346
Oliver, J. M., Burg, D. L., Wilson, B. S., McLaughlin, J. L., & Geahlen, R. L. (1994) · Journal of Biological Chemistry · doi:10.1016/s0021-9258(18)43936-1 · Cited by 338
POSITIVE VERSUS NEGATIVE SIGNALING BY LYMPHOCYTE ANTIGEN RECEPTORS
Healy, J. I., & Goodnow, C. C. (1998) · Annual Review of Immunology · doi:10.1146/annurev.immunol.16.1.645 · Cited by 316
Lanham, S., Hamblin, T., Oscier, D., Ibbotson, R., Stevenson, F., & Packham, G. (2003) · Blood · doi:10.1182/blood-2002-06-1822 · Cited by 315
Essential role of Src-family protein tyrosine kinases in NF-κB activation during B cell development
Saijo, K., Schmedt, C., Su, I.-H., Karasuyama, H., Lowell, C. A., Reth, M., Adachi, T., Patke, A., Santana, A., & Tarakhovsky, A. (2003) · Nature Immunology · doi:10.1038/ni893 · Cited by 305
Yousefi, S., Hoessli, D. C., Blaser, K., Mills, G. B., & Simon, H. U. (1996) · The Journal of experimental medicine · doi:10.1084/jem.183.4.1407 · Cited by 228
Gupta, S., Hastak, K., Afaq, F., Ahmad, N., & Mukhtar, H. (2004) · Oncogene · doi:10.1038/sj.onc.1207353 · Cited by 218
The B-cell antigen receptor complex: structure and signal transduction
Pleiman, C. M., D'Ambrosio, D., & Cambier, J. C. (1994) · Immunology Today · doi:10.1016/0167-5699(94)90267-4 · Cited by 200
Mahajan, S., Ghosh, S., Sudbeck, E. A., Zheng, Y., Downs, S., Hupke, M., & Uckun, F. M. (1999) · Journal of Biological Chemistry · doi:10.1074/jbc.274.14.9587 · Cited by 191
Bates, R. C., Edwards, N. S., Burns, G. F., & Fisher, D. E. (2001) · PubMed · Cited by 188
Positive and negative regulation of Src-family membrane kinases by CD45
Thomas, M. L., & Brown, E. J. (1999) · Immunology Today · doi:10.1016/s0167-5699(99)01506-6 · Cited by 178
Gupta, N., & DeFranco, A. L. (2003) · Molecular Biology of the Cell · doi:10.1091/mbc.02-05-0078 · Cited by 169
Pazdrak, K., Olszewska-Pazdrak, B., Stafford, S., Garofalo, R. P., & Alam, R. (1998) · The Journal of Experimental Medicine · doi:10.1084/jem.188.3.421 · Cited by 161
Burgel, P., Lazarus, S. C., Tam, D. C.-W., Ueki, I. F., Atabai, K., Birch, M., & Nadel, J. A. (2001) · The Journal of Immunology · doi:10.4049/jimmunol.167.10.5948 · Cited by 144
Wei, S., Liu, J. H., Epling‐Burnette, P. K., et al. (1996) · The Journal of Immunology · doi:10.4049/jimmunol.157.11.5155 · Cited by 123
Masdehors, P., Merle‐Béral, H., Maloum, K., Ōmura, S., Magdelénat, H., & Delić, J. (2000) · Blood · doi:10.1182/blood.v96.1.269 · Cited by 109
The molecular basis of glucocorticoid-induced apoptosis of lymphoblastic leukemia cells
Kofler, R. (2000) · Histochemistry and Cell Biology · doi:10.1007/s004180000165 · Cited by 101
Tse, K.-F., Allebach, J. P., Levis, M. J., Smith, B., Böhmer, F. D., & Small, D. (2002) · Leukemia · doi:10.1038/sj.leu.2402674 · Cited by 99
Activation of Src-like p56/p53lyn tyrosine kinase by ionizing radiation.
Kharbanda, S., Yuan, Z., Rubin, E. H., Weichselbaum, R. R., & Kufe, D. W. (1994) · Journal of Biological Chemistry · doi:10.1016/s0021-9258(17)32054-9 · Cited by 96
Aberrations of the B-Cell Receptor B29 (CD79b) Gene in Chronic Lymphocytic Leukemia
Thompson, A. A., Talley, J. A., Do, H. N., Kagan, H. L., Kunkel, L., Berenson, J., Cooper, M. D., Saxon, A., & Wall, R. (1997) · Blood · doi:10.1182/blood.v90.4.1387 · Cited by 92
Zomas, A., Matutes, E., Morilla, R. M., Owusu-Ankomah, K. A., Seon, B. K., & Catovsky, D. (1996) · PubMed · Cited by 91
Monoclonal Antibody Therapy of Chronic Lymphocytic Leukemia
Mavromatis, B. H., & Cheson, B. D. (2003) · Journal of Clinical Oncology · doi:10.1200/jco.2003.09.113 · Cited by 91
Luciano, F., Ricci, J., & Auberger, P. (2001) · Oncogene · doi:10.1038/sj.onc.1204661 · Cited by 63
Rituximab in B-Cell chronic lymphocytic leukemia
Lin, T. S., Lucas, M. S., & Byrd, J. C. (2003) · Seminars in Oncology · doi:10.1016/s0093-7754(03)00239-2 · Cited by 61
Molecular dissection of B cell antigen receptor signaling (review).
Kurosaki, T. (1998) · International Journal of Molecular Medicine · doi:10.3892/ijmm.1.3.515 · Cited by 47
Payelle‐Brogard, B., Magnac, C., Alcover, A., Roux, P., & Dighiero, G. (2002) · British Journal of Haematology · doi:10.1046/j.1365-2141.2002.03759.x · Cited by 43
Gordon, M. S., Kato, R. M., Lansigan, F., Thompson, A. A., Wall, R., & Rawlings, D. J. (2000) · Proceedings of the National Academy of Sciences · doi:10.1073/pnas.090087097 · Cited by 41
Deana, R., Turetta, L., Donà, M., Brunati, A. M., Michiel, L., Garbisa, S., & Donella‐Deana, A. (2003) · Thrombosis and Haemostasis · doi:10.1055/s-0037-1613474 · Cited by 40
Self-citationClinical Effects of Alemtuzumab (Campath-1H) in B-cell Chronic Lymphocytic Leukemia
Österborg, A., Mellstedt, H., & Keating, M. J. (2002) · Medical Oncology · doi:10.1385/mo:19:2s:s21 · Cited by 33
Stage as major long term outcome predictor in minor salivary gland carcinoma
Lutgendorf (2000) · Pure Amsterdam UMC · doi:10.1002/1097-0142(20000915)89:6 · Cited by 1
Cited by
Herman, S. E. M., Gordon, A. L., Hertlein, E., Ramanunni, A., Zhang, X., Jaglowski, S., Flynn, J., Jones, J., Blum, K. A., Buggy, J. J., et al. (2011) · Blood · doi:10.1182/blood-2011-01-328484 · Cited by 807
The B-cell receptor signaling pathway as a therapeutic target in CLL
Woyach, J. A., Johnson, A. J., & Byrd, J. C. (2012) · Blood · doi:10.1182/blood-2012-02-362624 · Cited by 412
B-cell receptor signaling in chronic lymphocytic leukemia
Stevenson, F. K., Krysov, S., Davies, A. J., Steele, A. J., & Packham, G. (2011) · Blood · doi:10.1182/blood-2011-06-338855 · Cited by 390
B cell receptor signaling in chronic lymphocytic leukemia
Burger, J. A., & Chiorazzi, N. (2013) · Trends in Immunology · doi:10.1016/j.it.2013.07.002 · Cited by 327
New insights into pre-BCR and BCR signalling with relevance to B cell malignancies
Rickert, R. C. (2013) · Nature Reviews Immunology · doi:10.1038/nri3487 · Cited by 288
Metadata
- Authors
- Contri, A., Brunati, A. M., Trentin, L., Cabrelle, A., Miorin, M., Cesaro, L., Pinna, L. A., Zambello, R., Semenzato, G., & Donella-Deana, A.
- Venue
- Journal of Clinical Investigation
- Published
- 2005-01-13
- Volume
- 115
- Issue
- 2
- Pages
- 369-378
- ISSN
- 0021-9738 (ISSN-L)
- OpenAlex
- W2003423830
- Cited by
- 261
- References
- 42
- FWCI
- 5.56
- Type
- journal article
- Language
- en
- Open access
- bronze
About these checks
Registry, retraction, Cites and statistics results are computed, not judged, with one exception: a printed reference that no index lists is read once by a model before it counts as a citation error. Claims are extracted by a model and kept only when their quote appears verbatim in the text; each cited source is then checked, with a model’s help, for whether it says what the claim relies on. Those verdicts can be wrong — read the claim’s quote and the cited source before relying on one.
Statistics and arithmetic are recomputed, not judged.
Confidence bands are shown only for fields calibrated on our annotated test set. None is calibrated yet, so no band is shown.
What counts as a claim ›How we measure confidence ›How we check this ›
Are you an author, or do you see a problem with this page? Request a review
Data sources
Bibliographic data: Semantic Scholar, OpenAlex, Crossref.
Contains information from the Semantic Scholar Academic Graph Datasets, made available under the ODC Attribution License (ODC-BY 1.0).
Semantic Scholar’s data is described in: Kinney, R., et al. (2023). The Semantic Scholar Open Data Platform. arXiv:2301.10140.